Structure-Based Discovery of the First Inhibitor Targeting the Talin2-β-integrin Interaction with Potent <i>In Vivo</i> Antitumor Activity in Breast Cancer Models
pharmacokinetic characteristics. In conclusion, Peptide-2 is a novel inhibitor that offers a potential new strategy for breast cancer therapy.
Authors
- Yunjiang Zhou (ORCID: https://orcid.org/0000-0003-0775-019X)
- Miaomiao Niu (ORCID: https://orcid.org/0000-0001-6368-8525)
- Yi Zhou (ORCID: https://orcid.org/0000-0002-0273-007X)
- Weiwei Hu (ORCID: https://orcid.org/0000-0001-6916-3746)
- Mengting Lou
- Shuting Li
- Lixia Guan
- Shutong Chen
Institutions
- China Pharmaceutical University (CN)
- Genesis Laboratories (US)
- Changzhou No.2 People's Hospital (CN)
- Nanjing Medical University (CN)
Publication Details
- Journal
- Journal of Medicinal Chemistry
- Published
- 2026-04-22
- DOI
- https://doi.org/10.1021/acs.jmedchem.5c03539
- Primary Topic
- Cell Adhesion Molecules Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00